Management Guidelines for Diabetic Patients With Hypertension
Corresponding Author
Weiqing Wang
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Correspondence:
Weiqing Wang ([email protected])
Search for more papers by this authorQin Wan
Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
Search for more papers by this authorGuang Ning
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorYufang Bi
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorLianyong Liu
Department of Endocrinology, Punan Hospital of Pudong New District, Shanghai, China
Search for more papers by this authorYan Liu
Department of Endocrinology, Third People's Hospital of Datong, Datong, China
Search for more papers by this authorYu Liu
Department of Endocrinology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China
Search for more papers by this authorXiaoying Li
Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China
Search for more papers by this authorTingzhi Li
Department of Endocrinology, Loudi First People's Hospital, Loudi, China
Search for more papers by this authorXueyi Wu
Department of Endocrinology, The Second People's Hospital of Guiyang, Guiyang, China
Search for more papers by this authorShengli Wu
Endocrine and Metabolism Center, Karamay Hospital of Traditional Chinese and Western medicine (Karamay People's Hospital), Karamay, China
Search for more papers by this authorYubo Sha
Department of Endocrine and Metabolic Diseases, The First People's Hospital of Dali, Dali, China
Search for more papers by this authorYifei Zhang
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorRongyue Chen
Department of Endocrinology, Xuchang Hongyue Diabetes Hospital, Xuchang, China
Search for more papers by this authorHongting Zheng
Department of Endocrinology, The Second Affiliated Hospital (Xinqiao Hospital) of Army Medical University, Chongqing, China
Search for more papers by this authorDong Zhao
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for more papers by this authorLing Hu
The Third Affiliated Hospital of Nanchang University (The First Hospital of Nanchang), Nanchang, China
Search for more papers by this authorPeng Duan
Department of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, China
Search for more papers by this authorXinguo Hou
Department of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, China
Search for more papers by this authorGuoyue Yuan
Department of Endocrinology, Affiliated Hospital of Jiangsu University, Zhenjiang, China
Search for more papers by this authorYu Xu
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorShan Huang
Department of Endocrinology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorZhiqiang Kang
Department of Endocrinology, Zhengzhou Central Hospital, Zhengzhou, China
Search for more papers by this authorQijuan Dong
Department of Endocrinology and Metabolism, People's Hospital of Zhengzhou, Zhengzhou, China
Search for more papers by this authorHuanfeng Pan
Department of Endocrinology, Jilin People's Hospital, Jilin, China
Search for more papers by this authorCorresponding Author
Weiqing Wang
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Correspondence:
Weiqing Wang ([email protected])
Search for more papers by this authorQin Wan
Department of Endocrinology and Metabolism, The Affiliated Hospital of Southwest Medical University, Luzhou, China
Search for more papers by this authorGuang Ning
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorYufang Bi
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorLianyong Liu
Department of Endocrinology, Punan Hospital of Pudong New District, Shanghai, China
Search for more papers by this authorYan Liu
Department of Endocrinology, Third People's Hospital of Datong, Datong, China
Search for more papers by this authorYu Liu
Department of Endocrinology, Sir Run Run Hospital, Nanjing Medical University, Nanjing, China
Search for more papers by this authorXiaoying Li
Department of Endocrinology, Zhongshan Hospital, Fudan University, Shanghai, China
Search for more papers by this authorTingzhi Li
Department of Endocrinology, Loudi First People's Hospital, Loudi, China
Search for more papers by this authorXueyi Wu
Department of Endocrinology, The Second People's Hospital of Guiyang, Guiyang, China
Search for more papers by this authorShengli Wu
Endocrine and Metabolism Center, Karamay Hospital of Traditional Chinese and Western medicine (Karamay People's Hospital), Karamay, China
Search for more papers by this authorYubo Sha
Department of Endocrine and Metabolic Diseases, The First People's Hospital of Dali, Dali, China
Search for more papers by this authorYifei Zhang
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorRongyue Chen
Department of Endocrinology, Xuchang Hongyue Diabetes Hospital, Xuchang, China
Search for more papers by this authorHongting Zheng
Department of Endocrinology, The Second Affiliated Hospital (Xinqiao Hospital) of Army Medical University, Chongqing, China
Search for more papers by this authorDong Zhao
Center for Endocrine Metabolism and Immune Diseases, Beijing Luhe Hospital, Capital Medical University, Beijing Key Laboratory of Diabetes Research and Care, Beijing, China
Search for more papers by this authorLing Hu
The Third Affiliated Hospital of Nanchang University (The First Hospital of Nanchang), Nanchang, China
Search for more papers by this authorPeng Duan
Department of Endocrinology and Metabolism, The Third Hospital of Nanchang, Nanchang, China
Search for more papers by this authorXinguo Hou
Department of Endocrinology and Metabolism, Qilu Hospital of Shandong University, Jinan, China
Search for more papers by this authorGuoyue Yuan
Department of Endocrinology, Affiliated Hospital of Jiangsu University, Zhenjiang, China
Search for more papers by this authorYu Xu
Department of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorShan Huang
Department of Endocrinology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Search for more papers by this authorZhiqiang Kang
Department of Endocrinology, Zhengzhou Central Hospital, Zhengzhou, China
Search for more papers by this authorQijuan Dong
Department of Endocrinology and Metabolism, People's Hospital of Zhengzhou, Zhengzhou, China
Search for more papers by this authorHuanfeng Pan
Department of Endocrinology, Jilin People's Hospital, Jilin, China
Search for more papers by this authorFunding: This work was supported by Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0508100).
ABSTRACT
Hypertension is one of the most common comorbidities associated with diabetes. The standardized diagnosis and treatment of hypertension in diabetic patients, along with achieving blood pressure targets, is of great significance for reducing long-term complications, extending lifespan, and improving quality of life. Recent high-quality multicenter large-sample intervention studies have provided important evidence-based grounds for setting blood pressure targets in diabetic patients. Therefore, based on a comprehensive summary of important domestic and international research literature, and in combination with clinical practice experience, this management guideline is now formulated.
Conflicts of Interest
The authors declare no conflicts of interest.
References
- 1L. Wang, W. Peng, Z. Zhao, et al., “Prevalence and Treatment of Diabetes in China, 2013-2018,” JAMA 326, no. 24 (2021): 2498–2506.
- 2 Writing Group of 2018 Chinese Guidelines for the Management of Hypertension, Chinese Hypertension League, Hypertension Branch of China International Exchange and Promotive Association for Medical and Health Care, et al., “2024 Chinese Guidelines for the Management of Hypertension,” Chinese Journal of Hypertension 32, no. 7 (2024): 603–700.
- 3M. Zhang, J. Wu, X. Zhang, et al., “Prevalence and Control of Hypertension in Adults in China, 2018,” Chinese Journal of Epidemiology 42, no. 10 (2021): 1780–1789.
- 4T. Wang, Y. Xu, M. Xu, et al., “Awareness, Treatment and Control of Cardiometabolic Disorders in Chinese Adults With Diabetes: A National Representative Population Study,” Cardiovascular Diabetology 14 (2015): 28.
- 5 American Diabetes Association Professional Practice C, “10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022,” Diabetes Care 45, no. Suppl 1 (2022): S144–S174.
- 6Q. Yang, R. Zheng, S. Wang, et al., “Systolic Blood Pressure Control Targets to Prevent Major Cardiovascular Events and Death in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis,” Hypertension 80, no. 8 (2023): 1640–1653.
- 7M. O'Donnell, A. Mente, M. H. Alderman, et al., “Salt and Cardiovascular Disease: Insufficient Evidence to Recommend Low Sodium Intake,” European Heart Journal 41, no. 35 (2020): 3363–3373, https://doi.org/10.1093/eurheartj/ehaa586.
- 8J. Chen, D. Gu, J. Huang, et al., “Metabolic Syndrome and Salt Sensitivity of Blood Pressure in Non-Diabetic People in China: A Dietary Intervention Study,” Lancet 373, no. 9666 (2009): 829–835.
- 9N. Sun, Y. Jiang, H. Wang, et al., “Survey on Sodium and Potassium Intake in Patients With Hypertension in China,” Journal of Clinical Hypertension 23, no. 11 (2021): 1957–1964.
- 10R. Schuler, M. A. Osterhoff, T. Frahnow, et al., “High-Saturated-Fat Diet Increases Circulating Angiotensin-Converting Enzyme, Which Is Enhanced by the rs4343 Polymorphism Defining Persons at Risk of Nutrient-Dependent Increases of Blood Pressure,” Journal of the American Heart Association 6, no. 1 (2017), https://doi.org/10.1161/JAHA.116.004465.
- 11Y. Luo, J. Wang, L. Sun, et al., “Isocaloric-Restricted Mediterranean Diet and Chinese Diets High or Low in Plants in Adults With Prediabetes,” Journal of Clinical Endocrinology and Metabolism 107, no. 8 (2022): 2216–2227.
- 12M. S. Kim, W. J. Kim, A. V. Khera, et al., “Association Between Adiposity and Cardiovascular Outcomes: An Umbrella Review and Meta-Analysis of Observational and Mendelian Randomization Studies,” European Heart Journal 42, no. 34 (2021): 3388–3403.
- 13L. Zhang, Z. Wang, X. Wang, et al., “Prevalence of Abdominal Obesity in China: Results From a Cross-Sectional Study of Nearly Half a Million Participants,” Obesity (Silver Spring) 27, no. 11 (2019): 1898–1905.
- 14 Hypertension Branch of the Chinese Geriatrics Society, Beijing Hypertension Prevention and Treatment Association, National Clinical Research Center of the Geriatric Diseases (Chinese PLA General Hospital, Xuanwu Hospital, Capital Medical University), et al., “2023 Chinese Guideline for the Management of Hypertension in the Elderl,” Chinese Journal of Hypertension 31, no. 6 (2023): 508–538.
- 15Y. Zhou, H. Zheng, E. Xue, et al., “A Prospective Cohort Study on the Association Between Smoking and Blood Pressure Among Middle-Aged and Elderly People,” Chinese Journal of Epidemiology 41, no. 6 (2020): 896–901.
- 16D. Pan, J. Guo, S. Wu, et al., “Association of Secondhand Smoke Exposure With All-Cause Mortality and Cardiovascular Death in Patients With Hypertension: Insights From NHANES,” Nutrition, Metabolism, and Cardiovascular Diseases 34, no. 7 (2024): 1779–1786.
- 17Y. Chen, C. Wang, Y. Liu, et al., “Incident Hypertension and Its Prediction Model in a Prospective Northern Urban Han Chinese Cohort Study,” Journal of Human Hypertension 30, no. 12 (2016): 794–800.
- 18F. Zhao, Q. Liu, Y. Li, X. Feng, H. Chang, and J. Lyu, “Association Between Alcohol Consumption and Hypertension in Chinese Adults: Findings From the CHNS,” Alcohol 83 (2020): 83–88.
- 19L. F. Lim, M. Solmi, and S. Cortese, “Association Between Anxiety and Hypertension in Adults: A Systematic Review and Meta-Analysis,” Neuroscience and Biobehavioral Reviews 131 (2021): 96–119.
- 20B. Hu, X. Liu, S. Yin, H. Fan, F. Feng, and J. Yuan, “Effects of Psychological Stress on Hypertension in Middle-Aged Chinese: A Cross-Sectional Study,” PLoS One 10, no. 6 (2015): e0129163.
- 21 Writing Group of 2018 Chinese Guidelines for the Management of Hypertension and L. Liu, “2018 Chinese Guidelines for the Management of Hypertension,” Prevention and Treatment of Cardio-Cerebrai-Vascuiar Disease 19, no. 1 (2019): 1–44.
- 22M. Tang, F. Wei, H. Zhang, et al., “Association Between Sleep and Prevalence of Hypertension in Elderly Population,” Chinese Journal of Epidemiology 42, no. 7 (2021): 1188–1193.
- 23L. Li, A. Yang, X. He, et al., “Indoor Air Pollution From Solid Fuels and Hypertension: A Systematic Review and Meta-Analysis,” Environmental Pollution 259 (2020): 113914.
- 24C. Mingji, I. J. Onakpoya, R. Perera, A. M. Ward, and C. J. Heneghan, “Relationship Between Altitude and the Prevalence of Hypertension in Tibet: A Systematic Review,” Heart 101, no. 13 (2015): 1054–1060.
- 25I. Avila-Palencia, D. A. Rodriguez, J. J. Miranda, et al., “Associations of Urban Environment Features With Hypertension and Blood Pressure Across 230 Latin American Cities,” Environmental Health Perspectives 130, no. 2 (2022): 27010.
- 26H. Ma, F. Liu, J. Li, et al., “Sex Differences in Associations Between Socioeconomic Status and Incident Hypertension Among Chinese Adults,” Hypertension 80, no. 4 (2023): 783–791.
- 27N. A. ElSayed, G. Aleppo, V. R. Aroda, et al., “Summary of Revisions: Standards of Care in Diabetes-2023,” Diabetes Care 46, no. Suppl 1 (2023): S5–S9.
- 28 SPRINT Research Group, J. T. Wright, Jr., J. D. Williamson, et al., “A Randomized Trial of Intensive Versus Standard Blood-Pressure Control,” New England Journal of Medicine 373, no. 22 (2015): 2103–2116, https://doi.org/10.1056/NEJMoa1511939.
- 29Y. Bi, M. Li, Y. Liu, et al., “Intensive Blood-Pressure Control in Patients With Type 2 Diabetes,” New England Journal of Medicine 392, no. 12 (2025): 1155–1167.
- 30 Academic Committee of Metabolic Management Center, Expert Advisory Committee of Metabolic Management Center, Council of Metabolic Management Center, et al., “Metabolic Disease Management Guideline for National Metabolic Management Center,” Chinese Journal of Endocrinology and Metabolism 39, no. 6 (2023): 538–554.
- 31 Chinese Society of Cardiology, Chinese Medical Association, Hypertension Committee of Cross-Straits Medicine Exchange Association, Cardiovascular Disease Prevention and Rehabilitation, Committee Chinese Association of Rehabilitation Medicine, et al., “Clinical Practice Guidelines for the Management of Hypertension in China,” Chinese Journal of Cardiology 52, no. 9 (2024): 985–1032.
- 32 Chinese Diabetes Society and D. Zhu, “Guideline for the Prevention and Treatment of Type 2 Diabetes Mellitus in China(2020 Edition),” Chinese Journal of Endocrinology and Metabolism 37, no. 4 (2021): 311–398.
- 33J. McMurray, S. D. Solomon, S. E. Inzucchi, et al., “Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction,” New England Journal of Medicine 381, no. 21 (2019): 1995–2008.
- 34D. K. McGuire, W. J. Shih, F. Cosentino, et al., “Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-Analysis,” JAMA Cardiology 6, no. 2 (2021): 148–158.
- 35H. C. Gerstein, H. M. Colhoun, G. R. Dagenais, et al., “Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial,” Lancet 394, no. 10193 (2019): 121–130.
- 36S. P. Marso, G. H. Daniels, K. Brown-Frandsen, et al., “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes,” New England Journal of Medicine 375, no. 4 (2016): 311–322.
- 37S. P. Marso, S. C. Bain, A. Consoli, et al., “Semaglutide and Cardiovascular Outcomes in Patients With Type 2 Diabetes,” New England Journal of Medicine 375, no. 19 (2016): 1834–1844.
- 38H. C. Gerstein, H. M. Colhoun, G. R. Dagenais, et al., “Dulaglutide and Renal Outcomes in Type 2 Diabetes: An Exploratory Analysis of the REWIND Randomised, Placebo-Controlled Trial,” Lancet 394, no. 10193 (2019): 131–138.
- 39J. Mann, T. Hansen, T. Idorn, et al., “Effects of Once-Weekly Subcutaneous Semaglutide on Kidney Function and Safety in Patients With Type 2 Diabetes: A Post-Hoc Analysis of the SUSTAIN 1-7 Randomised Controlled Trials,” Lancet Diabetes and Endocrinology 8, no. 11 (2020): 880–893.
- 40J. F. E. Mann, D. D. Ørsted, K. Brown-Frandsen, et al., “Liraglutide and Renal Outcomes in Type 2 Diabetes,” New England Journal of Medicine 377, no. 9 (2017): 839–848.
- 41A. I. Adler, R. L. Coleman, J. Leal, W. N. Whiteley, P. Clarke, and R. R. Holman, “Post-Trial Monitoring of a Randomised Controlled Trial of Intensive Glycaemic Control in Type 2 Diabetes Extended From 10 Years to 24 Years (UKPDS 91),” Lancet 404, no. 10448 (2024): 145–155.
- 42J. Hong, Y. Zhang, S. Lai, et al., “Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease,” Diabetes Care 36, no. 5 (2013): 1304–1311.
- 43H. C. Gerstein, R. L. Coleman, C. A. B. Scott, et al., “Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial,” Diabetes Care 43, no. 9 (2020): 2242–2247.
- 44Y. Gu, X. Wang, J. Li, et al., “Analyses of Gut Microbiota and Plasma Bile Acids Enable Stratification of Patients for Antidiabetic Treatment,” Nature Communications 8, no. 1 (2017): 1785.
- 45A. V. Hernandez, A. Usmani, A. Rajamanickam, et al., “Thiazolidinediones and Risk of Heart Failure in Patients With or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis and Meta-Regression Analysis of Placebo-Controlled Randomized Clinical Trials,” American Journal of Cardiovascular Drugs 11, no. 2 (2011): 115–128, https://doi.org/10.2165/11587580-000000000-00000.
- 46 ONTARGET Investigators, S. Yusuf, K. K. Teo, et al., “Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events,” New England Journal of Medicine 358, no. 15 (2008): 1547–1559, https://doi.org/10.1056/NEJMoa0801317.
- 47V. Lufft, B. Dannenberg, H. J. Schlitt, R. Pichlmayr, and R. Brunkhorst, “Cardiovascular Morbidity and Mortality in Patients With Diabetes Mellitus Type I After Kidney Transplantation: A Case-Control Study,” Clinical Nephrology 61, no. 4 (2004): 238–245, https://doi.org/10.5414/cnp61238.
- 48H. H. Parving, H. Lehnert, J. Brochner-Mortensen, et al., “The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients With Type 2 Diabetes,” New England Journal of Medicine 345, no. 12 (2001): 870–878.
- 49D. Coyle, R. Rodby, S. Soroka, et al., “Cost-Effectiveness of Irbesartan 300 Mg Given Early Versus Late in Patients With Hypertension and a History of Type 2 Diabetes and Renal Disease: A Canadian Perspective,” Clinical Therapeutics 29, no. 7 (2007): 1508–1523.
- 50J. G. Wang, K. Kario, T. Lau, et al., “Use of Dihydropyridine Calcium Channel Blockers in the Management of Hypertension in Eastern Asians: A Scientific Statement From the Asian Pacific Heart Association,” Hypertension Research 34, no. 4 (2011): 423–430.
- 51F. J. Al Badarin, M. A. Abuannadi, C. J. Lavie, et al., “Evidence-Based Diuretic Therapy for Improving Cardiovascular Prognosis in Systemic Hypertension,” American Journal of Cardiology 107, no. 8 (2011): 1178–1184.
- 52J. G. Cleland, A. P. Coletta, M. Lammiman, et al., “Clinical Trials Update From the European Society of Cardiology Meeting 2005: CARE-HF Extension Study, ESSENTIAL, CIBIS-III, S-ICD, ISSUE-2, STRIDE-2, SOFA, IMAGINE, PREAMI, SIRIUS-II and ACTIVE,” European Journal of Heart Failure 7, no. 6 (2005): 1070–1075.
- 53D. Castagno, P. S. Jhund, J. J. McMurray, et al., “Improved Survival With Bisoprolol in Patients With Heart Failure and Renal Impairment: An Analysis of the Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) Trial,” European Journal of Heart Failure 12, no. 6 (2010): 607–616, https://doi.org/10.1093/eurjhf/hfq038.
